18 January 2021
17 October 2020
Theramex is taking measures to secure continuity of supply of products to our patients in line with UK Government guidance following the transition period to exit UK from the European Union which ends on the 31st December 2020.
Since Theramex’s acquisition of Evorel® in October 2019, we made it a priority to relaunch and resupply the Evorel® portfolio into the UK by Quarter 1 – 2020. With our patient centric vision, we wanted to ensure that every woman who needs Evorel® can access it. We have therefore worked with multiple manufacturing partners to increase our production capacity and as a result as of 1st September 2020, Evorel® is fully in stock.
Our current projections show an increase in stock levels of Evorel® in the UK over the next few months. Due to the uncertainty surrounding a potential 2nd Wave of Covid 19 and the post Brexit situation, there may be disruption in our supply chain even though we have taken necessary measures to mitigate disruption such as instituting a policy of carrying three months of safety stock. It is our intention to remain agile and responsive to any challenges ahead and that we continue to serve our patients and safeguard their access to Evorel®.